Loading...
XNAS
TRAW
Market cap7mUSD
Aug 21, Last price  
0.53USD
1D
1.92%
1Q
-64.43%
Jan 2017
-100.00%
IPO
-100.00%
Name

Onconova Therapeutics Inc

Chart & performance

D1W1MN
XNAS:TRAW chart
P/E
0.88
P/S
2.89
EPS
0.60
Div yield, %
—
Shrs. gr., 5y
78.36%
Rev. gr., 5y
64.59%
Revenues
3m
+1,134.51%
1,487,00046,190,0004,753,000800,00011,456,0005,546,000787,0001,228,0002,183,000231,000226,000226,000226,000226,0002,790,000
Net income
9m
P
-30,314,000-33,865,000-64,863,000-63,682,000-23,979,000-19,667,000-24,092,000-20,573,000-21,503,000-25,157,000-16,163,000-18,964,000-18,948,000-54,674,0009,170,000
CFO
-18m
L-38.96%
-14,171,0001,633,000-61,384,000-57,648,000-31,313,000-15,813,000-23,820,000-22,696,000-20,831,000-23,075,000-19,487,000-16,294,000-17,932,000-29,792,000-18,185,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

The Fund seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of Onto Innovation Inc. (ONTO). The Fund will invest at least 80% of the value of its net assets, in financial instruments that provide leveraged exposure to the Underlying Security.
URL
https://www.onconova.com/
IPO date
Jul 25, 2013
Employees
16
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT